Soligenix Enters Securities Purchase Agreement with Investors on September 25: SEC Filing

Soligenix, a biopharmaceutical company, has entered a securities purchase agreement with investors, as per an SEC filing on September 25. The company is focused on developing and commercializing products for rare diseases, with programs including HyBryte for cutaneous T-cell lymphoma and RiVax for ricin toxin.

PRINCETON, N.J., Sept. 12, 2025 - Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases, has successfully closed a $7.5 million public offering. The offering involved the sale of 5,555,560 shares of common stock at a combined purchase price of $1.35 per share, along with warrants to purchase up to 5,555,560 shares of common stock at a combined purchase price of $1.35 per share. The warrants are exercisable immediately and will expire five years from the issuance date.

The company received aggregate gross proceeds of approximately $7.5 million before deducting placement agent fees and other offering expenses. The funds will be used to extend the company's cash runway through the end of 2026, providing sufficient funds for anticipated key inflection points in research and development and commercialization activities, working capital, and general corporate purposes.

Soligenix's Specialized BioTherapeutics business segment is developing HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). The company's Public Health Solutions business segment includes development programs for RiVax®, a ricin toxin vaccine candidate, and vaccine programs targeting filoviruses and CiVax™ for the prevention of COVID-19.

The company's existing warrants were amended to have a reduced exercise price of $1.35 per share and will expire commensurate with the warrants sold in the offering. This funding will support the company's ongoing efforts to develop and commercialize its products, particularly in the areas of rare diseases and public health solutions.

The securities described above were offered pursuant to a registration statement on Form S-1 (File No. 333-290413), previously filed with the Securities and Exchange Commission (SEC) on September 19, 2025, which became effective on September 25, 2025. The offering was made only by means of a prospectus forming part of the effective registration statement. Copies of the final prospectus relating to the offering may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at [A.G.P./Alliance Global Partners](mailto:).